Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between Equol Production Status and Nonalcoholic Steatohepatitis.
Akahane T, Kaya D, Noguchi R, Kaji K, Miyakawa H, Fujinaga Y, Tsuji Y, Takaya H, Sawada Y, Furukawa M, Kitagawa K, Ozutsumi T, Kawaratani H, Moriya K, Namisaki T, Yoshiji H. Akahane T, et al. Among authors: fujinaga y. Int J Mol Sci. 2021 Nov 2;22(21):11904. doi: 10.3390/ijms222111904. Int J Mol Sci. 2021. PMID: 34769332 Free PMC article.
[A case of infectious mononucleosis with splenic infarction].
Kobe D, Nakatani T, Fujinaga Y, Seki K, Saikawa S, Sawada Y, Sato Y, Nagamatsu S, Matsuo H, Kikuchi E. Kobe D, et al. Among authors: fujinaga y. Nihon Shokakibyo Gakkai Zasshi. 2013 Aug;110(8):1461-7. Nihon Shokakibyo Gakkai Zasshi. 2013. PMID: 23912006 Japanese.
Ancylostoma ceylanicum hookworm infection in Japanese traveler who presented chronic diarrhea after return from Lao People's Democratic Republic.
Kaya D, Yoshikawa M, Nakatani T, Tomo-Oka F, Fujimoto Y, Ishida K, Fujinaga Y, Aihara Y, Nagamatsu S, Matsuo E, Tokoro M, Ouji Y, Kikuchi E. Kaya D, et al. Among authors: fujinaga y. Parasitol Int. 2016 Dec;65(6 Pt A):737-740. doi: 10.1016/j.parint.2016.07.001. Epub 2016 Jul 20. Parasitol Int. 2016. PMID: 27450724
Glycogenic Hepatopathy in Type 1 Diabetes Mellitus.
Asada S, Kawaratani H, Mashitani T, Kaya D, Nishigori M, Kubo T, Sawada Y, Fujinaga Y, Kaji K, Kitade M, Namisaki T, Moriya K, Mitoro A, Yoshiji H. Asada S, et al. Among authors: fujinaga y. Intern Med. 2018 Apr 15;57(8):1087-1092. doi: 10.2169/internalmedicine.9490-17. Epub 2017 Dec 27. Intern Med. 2018. PMID: 29279489 Free PMC article.
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.
Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H. Namisaki T, et al. Among authors: fujinaga y. Hepatol Commun. 2017 Sep 19;1(9):928-945. doi: 10.1002/hep4.1104. eCollection 2017 Nov. Hepatol Commun. 2017. PMID: 29404501 Free PMC article.
Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.
Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Okura Y, et al. Among authors: fujinaga y. Hepatol Res. 2019 Feb;49(2):232-238. doi: 10.1111/hepr.13249. Epub 2018 Oct 9. Hepatol Res. 2019. PMID: 30198141
Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.
Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H. Takeda K, et al. Among authors: fujinaga y. Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19. Exp Ther Med. 2018. PMID: 30210615 Free PMC article.
Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H. Sawada Y, et al. Among authors: fujinaga y. Hepatol Res. 2019 Mar;49(3):284-295. doi: 10.1111/hepr.13281. Epub 2018 Dec 12. Hepatol Res. 2019. PMID: 30365236
Identification of clinical risk factors for histological progression of primary biliary cholangitis.
Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H. Fujinaga Y, et al. Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14. Hepatol Res. 2019. PMID: 31021038
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H. Shimozato N, et al. Among authors: fujinaga y. Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15. Hepatol Res. 2019. PMID: 31177586
326 results